海尔生物
Search documents
海尔生物:公司四大产业的市场竞争力加速提升
Zheng Quan Ri Bao Wang· 2026-01-09 12:19
Core Viewpoint - The company emphasizes that technological self-reliance is driving the industry towards domestic production, which further expands its development space and enhances market competitiveness across its four major industries [1] Market Position and Performance - The company's market share in the low-temperature storage industry continues to increase, with a projected market share of over 50% in plasma collection solutions by mid-2025, based on public and third-party bidding data [1] - The company ranks among the top three in the automated medication market and continues to break through in the domestic market for scientific instruments, with its total organic carbon analyzers and UV spectrophotometers being the top two domestic brands [1] - The centrifuge series has entered the top ten in market share among industry brands, while the biological safety cabinet has risen to the number one position nationwide, and the cultivation series maintains the highest market share among domestic brands [1] International Market Presence - Preliminary market research indicates that the company's three major low-temperature product lines hold the leading market share in 25 overseas countries [1]
海尔生物:公司将持续提升价值创造能力,不断强化信息披露工作
Zheng Quan Ri Bao· 2026-01-09 12:12
(文章来源:证券日报) 证券日报网讯 1月9日,海尔生物在互动平台回答投资者提问时表示,公司将持续提升价值创造能力, 不断强化信息披露工作,并通过各种方式增强与各类投资者的沟通,积极向资本市场传递公司价值。 ...
海尔生物:利润端有望在2026年迎来拐点
Zheng Quan Ri Bao Wang· 2026-01-09 11:49
证券日报网讯1月9日,海尔生物在互动平台回答投资者提问时表示,公司以价值创造能力的提升为己 任,坚持技术创新、场景升级和全球化发展来提升上市公司经营效率和盈利能力,并基于"大市场、小 细分、多产品、多应用"的行业特点,加快投资并购进程补强现有产业、扩大业务边界,重塑自身产业 发展格局,不断增强公司的核心竞争力和投资价值。基于行业的常态化发展和公司核心竞争力的提升, 经初步测算,随着新建产能逐步释放和创新品类加速放量,利润端有望在2026年迎来拐点(上述内容依 据目前可获得的公开信息及管理层初步测算做出,不构成公司对任何投资者或第三方的业绩承诺、盈利 预测或前瞻性陈述,敬请投资者注意风险)。 ...
海尔生物:截至2025年12月31日股东总数为13105户
Zheng Quan Ri Bao Wang· 2026-01-09 11:49
证券日报网讯1月9日,海尔生物在互动平台回答投资者提问时表示,截至2025年12月31日,公司股东总 数为13105户。 ...
海尔生物(688139) - 海尔生物关于完成工商变更登记并换发营业执照的公告
2026-01-09 08:00
证券代码:688139 证券简称:海尔生物 公告编号:2026-003 青岛海尔生物医疗股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性依 法承担法律责任。 1 法定代表人:刘占杰 注册资本:316,492,922 元 成立日期:2005 年 10 月 28 日 住所:山东省青岛市高新区丰源路 280 号 经营范围:医疗器械的技术研发、生产、销售、售后服务及维修保养;制冷 设备、机电设备、冷库、液氮生物容器、太阳能制冷产品、实验室设备、消毒器 械、自动化仪器设备、电子产品、通讯产品、家用及商用电器、汽车电器的技术 开发、生产、销售和售后服务;冷藏服务;物联网技术开发、咨询服务、系统集 成;自动化管理系统、计算机集成系统的技术开发、销售和运维服务;软件技术 开发、销售、运维服务和技术咨询;计算机网络技术开发、技术咨询;第二类增 值电信业务;互联网信息服务;医疗器械互联网信息服务;化工产品(不含危险 化学品及一类易制毒化学品)、生物制品、仪器仪表、实验室耗材、家具、办公 自动化设备的销售;汽 ...
华阳智能:公司主要客户为美的、格力等家用电器集团
Zheng Quan Ri Bao Zhi Sheng· 2026-01-08 13:36
Core Viewpoint - Huayang Intelligent has established itself as a significant player in the micro-special motor and component sector, with a strong reputation and stable market share, particularly in the air conditioning segment [1] Group 1: Micro-special Motors and Components - The company has developed a high level of industry expertise over the years and serves major clients such as Midea, Gree, Haier, Hisense, and Aux [1] - The market demand for micro-special motors is expected to increase due to the home appliance industry's shift towards high-end, integrated, and intelligent products, as well as the expansion of the central air conditioning market [1] Group 2: Precision Drug Delivery Devices - In the precision drug delivery device sector, the company is one of the earliest entrants in China and holds a leading position with a comprehensive product line [1] - Major clients include domestic and international biopharmaceutical companies such as Jinsai Pharmaceutical, Haosen Pharmaceutical, and Corning Jereh [1] - The company's products have successfully adapted to various drug delivery needs, including recombinant human growth hormone and insulin, and are continuously exploring applications for new drug types [1] - The precision drug delivery device business is anticipated to enter a phase of accelerated growth due to the steady increase in the market for existing applicable drugs and the ongoing development of new drug applications [1]
2026年A股并购市场投资展望
国泰海通· 2026-01-08 05:20
Group 1: Market Overview - In 2026, the A-share M&A market is expected to focus on three main industrial lines: hard technology, cyclical industries, and state-owned enterprise restructuring[2] - The macroeconomic environment will emphasize the synergy between capital markets and the real economy, supported by a moderately loose monetary policy to lower financing costs[9] - In 2025, the A-share M&A market saw 1,632 asset acquisition announcements, a 14% increase year-on-year, with significant asset restructuring transactions rising by 80%[10] Group 2: Industrial Lines - The hard technology sector will be a key focus, with mergers in AI applications, commercial aerospace, and humanoid robotics expected to accelerate[17] - Cyclical industries will see consolidation through supply-side reforms, particularly in solar energy, automotive, and brokerage sectors, with a focus on optimizing supply-demand structures[22] - State-owned enterprises are anticipated to engage in significant asset restructuring and mergers, with a focus on strategic and commercial asset injections[25] Group 3: Transaction Lines - Control transactions in listed companies are expected to show structural differentiation, with a shift towards "industrial logic" rather than "arbitrage logic" due to regulatory changes[27] - The role of state-owned capital in M&A funds is expected to grow, with 29 new funds established in 2025, targeting over 100 billion yuan in total[32] - Innovative cross-border M&A transactions are likely to continue, with a focus on integrating global high-quality technology assets and enhancing A+H market synergy[37] Group 4: Risks and Challenges - M&A transactions involving equity stakes face higher uncertainties compared to cash transactions, with financial capacity of listed companies significantly impacting deal success[41] - The tightening of regulatory policies may increase the difficulty of mergers, particularly for cross-border transactions and those involving shell companies[41] - The restructuring of ST companies presents both opportunities and high risks, dependent on the successful execution of restructuring plans[43]
格力CMO朱磊微博炮轰创维抄袭空调海报
Xin Lang Ke Ji· 2026-01-07 02:58
【#格力电器CMO炮轰创维抄袭##格力朱磊让创维下次别抄了#】格力电器CMO朱磊于微博发文炮轰创 维电器称,"抄得挺像的,下次别抄了。" 据朱磊发布配图内容,于创维空调官方视频号发布的一则创维空调海报设计页面,与格力推出的"真铜 实料 格力造"海报高度相似,明显涉嫌抄袭。 不过,目前该发布于创维空调视频号的海报已经删除。对于涉嫌抄袭一事,截至发稿创维方面暂无回 应。(新浪科技) ...
“海尔系”再扩资本版图:海尔新能源启动IPO辅导
Zhong Guo Jing Ying Bao· 2026-01-06 07:23
中经记者 张英英 吴可仲 北京报道 海尔集团的资本布局再落一子。 近日,海尔集团旗下新能源公司——海尔新能源科技股份有限公司(以下简称"海尔新能源")首次公开 发行股票并上市辅导备案报告正式披露,其辅导机构为国泰海通。 关于此次IPO事宜,截至发稿,海尔新能源方面未向《中国经营报》记者置评。 创立于1984年的海尔集团,其业务及投资已延伸至多个领域。目前,海尔集团旗下资本版图已囊括海尔 智家、雷神科技、海尔生物、盈康生命、上海莱士、新时达、汽车之家、众淼控股等多家上市公司。 2024年9月,海尔集团旗下有屋智能登陆新三板。 此次海尔新能源若成功上市,将进一步扩充海尔集团的资本版图。 公开资料显示,海尔新能源成立于2022年5月11日,注册资本3.37亿元,法定代表人为董增。该公司控 股股东为海尔集团全资子公司青岛纳晖控股有限公司,后者直接持股59.4%。 2025年4月,海尔新能源完成超7亿元的A轮融资,获得国投创益、中国石油昆仑资本、普超资本、星航 资本、恒旭资本等资方投资。同年12月,海尔新能源获评"全球独角兽企业"。 从业务上看,海尔新能源聚焦"绿能+储能+智慧能源控制器",为家庭及工商业用户提供光伏、 ...
海尔生物:累计回购约305万股
Mei Ri Jing Ji Xin Wen· 2026-01-05 11:34
每经AI快讯,海尔生物1月5日晚间发布公告称,截至2025年12月31日,公司通过上海证券交易所交易 系统以集中竞价交易方式累计回购公司股份约305万股,占公司总股本约3.18亿股的比例为0.9604%,回 购成交的最高价为34.69元/股,最低价为29.86元/股支付的资金总额为人民币约9890万元。 (记者 王晓波) 每经头条(nbdtoutiao)——秒光!1499元飞天茅台上线即空,i茅台App冲上苹果购物榜第一,10万用 户已下单!经销商同价做回馈,1000箱很快卖完 ...